Fluidigm, DVS Sciences deal

Microfluidics company Fluidigm is acquiring DVS Sciences for about $207.5 million in a cash and stock deal. DVS develops and markets single-cell protein analysis systems, including its CyTOF2 mass cytometer. Fluidigm said DVS will complement Fluidigm's single-cell genomics technologies. In January, Fluidigm said it expects 2013 total revenue of $71 million. DVS - which is backed by 5AM Ventures; Pfizer Venture Investments; Mohr Davidow; Roche Venture Fund; and the Ontario Institute for Cancer Research - had $18.5 million in revenue for the nine months ended Sept. 30, 2013. ...